ライフサイエンスコーパス: INSTI

1 (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R virus).

2 genotype; 12-week suppression rates are 90% (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R viru

3 Prevalence was stable, although INSTIs were increasingly used.

4 hydro-1,8-naphthyridine-3-carboxamides as an INSTI scaffold, making a limited set of derivatives, and

5 ties of Determine, Uni-Gold, SD Bioline, and INSTI were 99.8%.

6 and IN mutations are important for NNRTI and INSTI resistance and viral fitness.

7 ore potential interactions between NNRTI and INSTI resistance mutations, we investigated the combined

8 inhibition of the 3'-processing reaction by INSTIs and how INSTIs can be modified to overcome drug r

9 of bictegravir, a novel, potent, once-daily INSTI designed to improve on existing INSTI options with

10 rate envelope concept that broadly effective INSTIs can be designed by filling the envelope defined b

11 atives, and concluded that broadly effective INSTIs can be developed using this scaffold.

12 -daily INSTI designed to improve on existing INSTI options with the backbone of emtricitabine and ten

13 Pretreatment assessment for INSTI resistance should not be recommended in treatment

14 ecently approved the first second generation INSTI, GSK's Dolutegravir (DTG) (August 2013).

15 New "2nd-generation" INSTIs are needed that will have greater efficacy agains

16 the 3'-processing reaction by INSTIs and how INSTIs can be modified to overcome drug resistance, nota

17 hat of the second generation INST inhibitor (INSTI) dolutegravir.

18 eration integrase strand transfer inhibitor (INSTI), was recently approved for use in the treatment o

19 smitted integrase strand transfer inhibitor (INSTI)-resistant (INSTI-R) virus is estimated at 0.1%.

20 ence of integrase strand transfer inhibitor (INSTI)-transmitted drug resistance (TDR) may increase wi

21 d integrase (IN) strand transfer inhibitors (INSTI) are key components of antiretroviral regimens.

22 1 integrase (IN) strand transfer inhibitors (INSTIs) approved by the FDA for the treatment of AIDS.

23 Integrase strand transfer inhibitors (INSTIs) are highly effective against HIV infections.

24 Integrase strand transfer inhibitors (INSTIs) are recommended components of initial antiretrov

25 ommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy.

26 Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide

27 s were proven IN strand transfer inhibitors (INSTIs) that also displayed activity against ribonucleas

28 These IN strand-transfer inhibitors (INSTIs) were evaluated in vitro in cell-free enzyme acti

29 proved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG).

30 which act as IN strand transfer inhibitors (INSTIs), were the first anti-IN drugs to be approved by

31 tter efficacy against a broad panel of known INSTI resistant mutants than any analogues we have previ

32 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected.

33 ial HIV-1 treatment with bictegravir-a novel INSTI with a high in-vitro barrier to resistance and low

34 No effect of INSTI resistance mutations on the fitness of RT-Y181C mu

35 We analyzed the prevalence of INSTI TDR in the Swiss HIV Cohort Study (2008-2014).

36 d Uni-Gold were 100%, and the specificity of INSTI was 99.8%.

37 inically preferred unless DTG suppression of INSTI-R virus was <20% or 96-week DRV/r suppression was

38 examining the role of the MBG in a series of INSTIs, we have identified a scaffold (hydroxypyrones) t

39 TDR) may increase with the increasing use of INSTIs.

40 rticipants harboring resistance to the other INSTIs, raltegravir and elvitegravir.

41 tion that mutant viruses carrying NNRTI plus INSTI resistance mutations had reduced amounts of virion

42 Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance and low

43 strand transfer inhibitor (INSTI)-resistant (INSTI-R) virus is estimated at 0.1%.

44 ing, all patients are diagnosed with INSTI-S/INSTI-R virus prior to ART initiation and start DTG- or

45 uppression rates are 90% (INSTI-susceptible [INSTI-S] virus) and 35% (INSTI-R virus).

46 Using the INSTI Multiplex downward-flow immunoassay, we tested 200

47 Prevalence of transmitted INSTI-R virus did not affect the favored strategy.

48 Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy st

49 weeks undergo IR testing; if diagnosed with INSTI-R virus, they change to ritonavir-boosted darunavi

50 IR testing, all patients are diagnosed with INSTI-S/INSTI-R virus prior to ART initiation and start